Clinical TrialID 5601

Vaginal Estriol in Multiple Sclerosis

NCT03774407

Multiple Sclerosis|Neurogenic Bladder

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
5601
Evidence Id
5601
Core Evidence Id
5601
Source Clinical Trial Id
5586
Herb2 Clinical Trial Id
HBCT005586
Nct Id
NCT03774407
Title
Vaginal Estriol in Multiple Sclerosis
Status
Completed
Phase
Phase 2|Phase 3
Study Result
Yes
Study Condition
Multiple Sclerosis|Neurogenic Bladder
Study Type
Interventional
Study Design
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Intervention
DRUG: vaginal estriol
Intervention Allocation
Non_Randomized
Intervention Model
Parallel
Intervention Mask
Intervention Purpose
Treatment
Gender
Female
Age
Adult, Older_Adult
Enrollment
21
Outcome Measure
Change in Bladder Control Scale (BLCS), The questions are regarding control of the bladder, number of accidents in the past 4 weeks, alteration of activities because of bladder problems and restriction on lifestyle because of bladder problems. The total score for the BLCS is the sum of the scores for the 4 items. Scores can range from 0-22, with higher scores indicating greater bladder control problems. Change from baseline at 9 months., baseline and 9 months|Change in Visual Evoked Potential and Ocular Tomography Results From Baseline to 9 Months of Both Eyes, visual evoked potential measured in each eye at baseline and 9 months normal value should be bellow 100 milliseconds, Baseline and 9 months|Change in MS Quality of Life Questionnaire at Baseline and 9 Months. (Physical Score), Multiple sclerosis quality of life questionnaire is an extensive questionnaire filled by the patient and graded by physician. It consists of 2 main areas the physical health which include physical function, health perceptions, energy fatigue, role limitations, pain, sexual function, social function and health distress. The mental health score which includes health distress, overall quality of life, emotional wellbeing, role limitations and cognitive function. The physical health and mental health parts each include a possible score range of 0-100. Overall the lower the score the better, Quality of life score at baseline and Quality of life score at 9 months
Sponsor Collaborator
Texas Tech University Health Sciences Center
Funded By
OTHER
Location
Texas Tech University Health Sciences Center, Lubbock, Texas, 79430, United States
Other Id
L19-020
Start Date
2019-06-20
Primary Completion Date
2020-11-10
Completion Date
2020-11-29
First Posted
2018-12-13
Results First Posted
2022-09-21
Last Update Posted
2022-09-21
Study Document
Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/07/NCT03774407/Prot_SAP_002.pdf|Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/07/NCT03774407/ICF_000.pdf
Study Url
https://clinicaltrials.gov/study/NCT03774407
Title Cn
Title En
Vaginal Estriol in Multiple Sclerosis
Bilingual Status
semi_complete